Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Eaton Corporation plc (ETN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Eaton Corporation plc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Eaton Corporation plc trades at $398 (market cap $153.64B). The key difference: Eaton Corporation plc is far larger — about 34.2× ACADIA Pharmaceuticals Inc.'s market cap, and Eaton Corporation plc pays a 1.11% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ETN | |
|---|---|---|
Market Cap | $4.49B | $153.64B |
Sector | Health | Technology |
52-Week High | $28.06 | $435.78 |
52-Week Low | $20.06 | $315.82 |
Enterprise Value | $3.69B | $174.72B |
Dividend Yield | — | 1.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Eaton (ETN) trades at $413.42, up 3.74% with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 20.87% ROE and 13.99% net margin, though valuation ratios like a 40.45 P/E are elevated. Recent news highlights sustainability investments and AI infrastructure opportunities, while analyst consensus remains strongly positive with a $449.50 price target.
Outlook is supported by earnings momentum and sector tailwinds, but high valuation and competitive pressures pose risks. The absence of sell ratings and institutional bullishness suggest upside potential, though investors should weigh growth against premium multiples in a volatile market environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →
